Neuron Stem Cells (iNSC) is under clinical development by Allife Medical Science and Technology and currently in Phase II for Parkinson’s Disease. According to GlobalData, Phase II drugs for Parkinson’s Disease have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Neuron Stem Cells (iNSC)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Neuron Stem Cells (iNSC) overview
Stem cell therapy is under development for the treatment of amyotrophic lateral sclerosis (ALS), Parkinson’s disease and ischemic stroke. The therapeutic candidate comprises of human autologous induced pluripotent (iPS) derived neural stem cells (NSC).
For a complete picture of Neuron Stem Cells (iNSC)’s drug-specific PTSR and LoA scores, buy the report here.